Which JNJ catheter received FDA approval?

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a catheter using both radiofrequency and pulsed field energy for atrial fibrillation treatment.

What is the advantage of the new catheter over existing devices?

It allows using both RF and pulsed field energy from a single device, simplifying procedures and reducing the need for device switching.

Has JNJ announced the price of the new catheter?

No, pricing has not been disclosed yet.

JNJ Gets FDA Nod for Dual-Energy Catheter, Boosting Electrophysiology

Johnson & Johnson (JNJ) has received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a single catheter capable of delivering both radiofrequency and pulsed field energy, simplifying atrial fibrillation ablation procedures.

JNJ's Dual-Energy Catheter Gains FDA Approval

Johnson & Johnson (JNJ) has secured U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a novel ablation catheter for treating atrial fibrillation. The catheter allows physicians to use both radiofrequency (RF) and pulsed field (PF) energy from a single device, streamlining workflow and enhancing procedure efficiency.

The Product

The catheter represents a leap in electrophysiology, combining two energy modalities in one device and integrating with JNJ's CARTO mapping system. This integration enables precise heart mapping and catheter guidance.

Pricing and Availability

Pricing has not been disclosed. U.S. procedures are expected to begin after a phased commercial rollout this summer.

Competition

The new catheter faces competition from similar devices by Medtronic and Boston Scientific, which have also developed pulsed field ablation technologies. However, the single-catheter dual-energy design may give JNJ a competitive edge.

Potential Impact on JNJ

The approval is expected to strengthen JNJ's position in the rapidly growing atrial fibrillation treatment market. This innovation could boost its market share in electrophysiology, positively impacting its medical devices segment revenue.